Redx Pharma Plc announced that it will present preclinical data from its recently-nominated development candidate, RXC009 at the American Society of Nephrology (ASN) Annual Meeting (2-5 November 2023, Philadelphia, PA). Redx nominated RXC009 as a development candidate in October 2023. RXC009 is a small molecule, orally available, highly potent and selective DDR1 inhibitor and a potential first-in-class treatment for chronic kidney disease (CKD).

CKD affects 8% to 16% of the population worldwide and is most commonly attributed to diabetes and hypertension. Renal fibrosis, characterized by tubulointerstitial fibrosis and glomerulosclerosis, is one of the final manifestations of CKD as it progresses and is associated with high morbidity. DDRs have recently gained traction as druggable targets with the potential to treat multiple fibrotic conditions, including kidney fibrosis associated with CKD such as in Alport Syndrome, butto date, no selective inhibitors of DDR1 have entered the clinic.